This HTML5 document contains 119 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
n12http://dx.doi.org/10.1093/ANNONC/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n4http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q57758019
rdf:type
wikibase:Item
schema:description
article scientifique publié en 2012 article artículu científicu im Oktober 2012 veröffentlichter wissenschaftlicher Artikel наукова стаття, опублікована в жовтні 2012 wetenschappelijk artikel
p:P577
wds:Q57758019-4D3AFDBD-71CC-4CBE-B9CE-DA9DEC0FFF56
wdt:P577
2012-10-05T00:00:00Z
p:P2860
wds:Q57758019-936E2C60-0479-4074-B714-784DC650C77D wds:Q57758019-A23EA155-31F4-4D94-ABB4-304F53AADDBA wds:Q57758019-D658473F-AF91-4354-9838-647DDC07E358 wds:Q57758019-E5E38506-3EBC-40BA-8F19-C97614B3C048 wds:Q57758019-ECAC16ED-20F4-40F8-91C1-36DE5EA75FBB wds:Q57758019-EDBC8D39-581D-433E-B034-E3F538988882 wds:Q57758019-074FA107-5105-4D24-AA8F-610F9B46E9E7 wds:Q57758019-078C21F7-0E03-48B9-B122-91AE15A1841E wds:Q57758019-081D0E18-1EE0-497B-AFC8-D43B59388AB1 wds:Q57758019-0967BED7-8224-4BBD-8DAC-FBC52518A4B7 wds:Q57758019-28DACA0C-E3ED-4E7F-AE78-AF6FABD9ACCC wds:Q57758019-56B5E920-9B8D-48D0-9EA5-E1AC7648B4DE wds:Q57758019-5EFF3ABA-3EBD-4F18-BB47-331DC6E4633F wds:Q57758019-6F068B36-5131-461D-A8D9-4A5CC530B28A wds:Q57758019-743322A9-0BDB-40E7-A0AA-016328921DD6
wdt:P2860
wd:Q44025718 wd:Q46107051 wd:Q29547903 wd:Q34622672 wd:Q27861075 wd:Q37058011 wd:Q45982820 wd:Q37263149 wd:Q34468844 wd:Q37157688 wd:Q28235646 wd:Q37639132 wd:Q27860562 wd:Q58811082 wd:Q44450344
p:P2093
wds:Q57758019-3AA32D7F-121F-482E-8B8F-9086CA08E16F wds:Q57758019-25C183A3-C9C2-4D9B-A4F4-BE20A2FBF3E2 wds:Q57758019-22F6F19C-A612-4046-8734-7326EDA41DB4 wds:Q57758019-6F606229-7581-4841-BA48-FE9291D6941F wds:Q57758019-5C008C32-D71F-466E-BAA4-128376B3DFBD wds:Q57758019-5BBED841-7CC8-4F3E-BC31-908E795693DC wds:Q57758019-038BACD1-0F4A-4B73-877D-C2F5E335DC44 wds:Q57758019-1C435C34-5F87-46BB-99D9-2FF4BDCCC8DE wds:Q57758019-22A3B1A6-2C5E-4C65-8966-FE82A07DAE73 wds:Q57758019-1877B153-7001-464D-A31B-9BBA1C73E61C wds:Q57758019-0948CA67-2CBB-40FA-95D7-89149A456821 wds:Q57758019-C6B50AAC-9FA1-4A06-BC37-8A01268CB870 wds:Q57758019-FFD4B934-0475-4C7B-916E-EF67A9FCCC5E wds:Q57758019-F3C56265-4C86-40B9-AEB7-53B68764EEAE wds:Q57758019-7789AACC-2441-41E1-80B8-0771ECD4D9F9 wds:Q57758019-7D5EE998-27B8-4B64-AE36-8806C3085D7A wds:Q57758019-B319B9EA-CD68-47E9-B26E-DE02337229D5 wds:Q57758019-A6D1E609-B92E-4743-AC78-EA582F4EE62C wds:Q57758019-914619C3-E7AD-4824-A6E8-70A9482E2DC2 wds:Q57758019-92B77CB9-F106-484B-B6CC-304F90D24A74
wdt:P2093
D Ferrari L Latini N Locopo R Ceriani M Banzi M A Tommasini F R Lutman T Pressiani S Fanello M De Giorgio S Naimo S Fagiuoli C Mucciarini S Salvagni E Cortesi M C Tronconi C Carnaghi G Covini C Boni A Santoro
rdfs:label
Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis
skos:prefLabel
Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis
schema:name
Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis
p:P50
wds:Q57758019-EC51327D-7166-467E-A914-D781E2CB3074 wds:Q57758019-CDD45C87-0516-43F5-9D26-5F13CF07A5CD wds:Q57758019-CE5D7545-AD9E-4C3A-B6DB-79D9701B3236 wds:Q57758019-701980FA-7620-4393-82B4-B3B13B72886B wds:Q57758019-6F1C28E9-94EF-4328-AF6E-8CBF6B47D8CB wds:Q57758019-37AE67BA-D268-4EFF-ACFA-FA45B057F70A
wdt:P50
wd:Q38524354 wd:Q37393105 wd:Q55069830 wd:Q56335956 wd:Q39950156 wd:Q72990110
p:P1476
wds:Q57758019-8576BDF0-9708-4D81-842A-9EB17348E1B7
wdt:P1476
Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis
p:P304
wds:Q57758019-AED8BE3D-52FD-4EC2-857D-8755309148ED
wdt:P304
406-411
p:P31
wds:Q57758019-453B3342-D353-4CB6-BB6E-B1AAEBF6F67F
wdt:P31
wd:Q13442814
p:P921
wds:Q57758019-235B5A23-B8E7-4A74-BF08-18500E67EAB7 wds:Q57758019-7F387933-49C7-481E-9B60-72F0E4EAD561
wdt:P921
wd:Q1148337 wd:Q181600
p:P698
wds:Q57758019-87E1A60D-E1FF-4AD9-B4E4-39125FFD3F59
wdtn:P698
n4:23041587
wdt:P698
23041587
p:P1433
wds:Q57758019-A54135FE-B991-4EA0-9053-D5EB4635CB2D
wdt:P1433
wd:Q326122
p:P433
wds:Q57758019-8E0CB242-3144-4663-ABFE-D28C91DF58F5
p:P478
wds:Q57758019-D63E7988-7692-49ED-AA93-E14850810BD0
wdt:P433
2
wdt:P478
24
p:P356
wds:Q57758019-6F44D97F-83E7-472C-87ED-6D4B2FE11AB8
wdtn:P356
n12:MDS343
wdt:P356
10.1093/ANNONC/MDS343